Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation
PHASE1
Primary Objectives:
* VCDI cohort:
* To determine the maximum tolerated...
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
PHASE2
This is a single-arm, open-label study to evaluate the efficacy and safety ...
Status
Recruiting
Location
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
PHASE3
This study is designed as a multicenter, randomized, parallel groups, open-...